Shalby Limited — Investor Meet, 20-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Shalby's Q2 FY26 saw consolidated revenue up 5.5% to INR 289 Cr, with PAT soaring 200% to INR 7.3 Cr. MedTech revenue jumped 42.1% to INR 33.7 Cr, turning EBITDA positive. Standalone revenue grew 5.6% to INR 230 Cr, PAT up 14% to INR 19.8 Cr, with EBITDA margin at 19.5%.

Management outlined plans to revive Shalby International Hospital (rebranded), expecting positive EBITDA next year. They address Q2's softer volumes due to monsoons and TPA negotiations, anticipating H2 recovery with new doctors and closing TPA deals. Operational metrics show ARPOB up 5.2% and occupancy at 48%. The company is investing in robotic surgeries and oncology infrastructure. MedTech focuses on new products, robotics, and supply chain efficiency, targeting sustainable growth. Ortho revenue mix is now 34%, showing diversification. CGHS rate revisions and GST are expected to positively impact margins and revenues. Management conveys a confident outlook on sustained operational and financial improvements.